Cargando…

Impact of coronavirus disease 2019 on contraception use in France

To limit the spread of the coronavirus disease 2019 (COVID 19), sanitary restrictions have been established since March 2020 in France. These restrictions and the waves of contamination may have had consequences on the use of health products in general, and on the use of contraceptives in particular...

Descripción completa

Detalles Bibliográficos
Autores principales: Roland, Noémie, Drouin, Jérôme, Desplas, David, Duranteau, Lise, Cuenot, François, Dray-Spira, Rosemary, Weill, Alain, Zureik, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851715/
https://www.ncbi.nlm.nih.gov/pubmed/36732137
http://dx.doi.org/10.1016/j.therap.2023.01.002
_version_ 1784872460686983168
author Roland, Noémie
Drouin, Jérôme
Desplas, David
Duranteau, Lise
Cuenot, François
Dray-Spira, Rosemary
Weill, Alain
Zureik, Mahmoud
author_facet Roland, Noémie
Drouin, Jérôme
Desplas, David
Duranteau, Lise
Cuenot, François
Dray-Spira, Rosemary
Weill, Alain
Zureik, Mahmoud
author_sort Roland, Noémie
collection PubMed
description To limit the spread of the coronavirus disease 2019 (COVID 19), sanitary restrictions have been established since March 2020 in France. These restrictions and the waves of contamination may have had consequences on the use of health products in general, and on the use of contraceptives in particular. We aimed to assess the impact of COVID 19 pandemic from March 16th 2020 to April 30th 2021 in France on reimbursed contraceptives. We analyzed data from the French national health insurance database (SNDS) by extracting all oral contraception (OC), emergency contraception (EC), levonorgestrel-intrauterine system (LNG-IUS), copper-intrauterine device (C-IUD) and contraceptive implant dispensations in 2018, 2019, 2020 and to April 30th 2021. We computed the expected use of contraceptives in 2020 and 2021 without pandemic and its associated sanitary restrictions, by taking the annual trend into account. We assessed the evolution of dispensations by type of contraceptive and by age-groups (≤25 years old, between 25 and 35 and >35 years old) between observed and expected dispensations. After 15 months of pandemic, a decrease of all reimbursed contraceptives dispensations had been estimated, compared with what was expected: –2.0% for OC, –5.0% for EC, –9.5% for LNG-IUS, –8.6% for C-IUD, –16.4% for implant. Women under 25 years old were the most impacted by the decrease. This national study showed that the impact of the COVID 19 crisis was global on all reimbursed contraceptives, with different levels of impact depending on the type of contraceptive, the age-group and the severity of the restriction. OC dispensing decreased marginally compared with expectations. The decrease in long-acting contraceptives dispensing was more pronounced, especially for the implant. These results call for continued monitoring of contraceptive use over the long term and for prioritizing access to sexual health services during crises, especially among the youngest women who were most affected in this study.
format Online
Article
Text
id pubmed-9851715
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Author(s). Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique.
record_format MEDLINE/PubMed
spelling pubmed-98517152023-01-20 Impact of coronavirus disease 2019 on contraception use in France Roland, Noémie Drouin, Jérôme Desplas, David Duranteau, Lise Cuenot, François Dray-Spira, Rosemary Weill, Alain Zureik, Mahmoud Therapie Pharmacoepidemiology To limit the spread of the coronavirus disease 2019 (COVID 19), sanitary restrictions have been established since March 2020 in France. These restrictions and the waves of contamination may have had consequences on the use of health products in general, and on the use of contraceptives in particular. We aimed to assess the impact of COVID 19 pandemic from March 16th 2020 to April 30th 2021 in France on reimbursed contraceptives. We analyzed data from the French national health insurance database (SNDS) by extracting all oral contraception (OC), emergency contraception (EC), levonorgestrel-intrauterine system (LNG-IUS), copper-intrauterine device (C-IUD) and contraceptive implant dispensations in 2018, 2019, 2020 and to April 30th 2021. We computed the expected use of contraceptives in 2020 and 2021 without pandemic and its associated sanitary restrictions, by taking the annual trend into account. We assessed the evolution of dispensations by type of contraceptive and by age-groups (≤25 years old, between 25 and 35 and >35 years old) between observed and expected dispensations. After 15 months of pandemic, a decrease of all reimbursed contraceptives dispensations had been estimated, compared with what was expected: –2.0% for OC, –5.0% for EC, –9.5% for LNG-IUS, –8.6% for C-IUD, –16.4% for implant. Women under 25 years old were the most impacted by the decrease. This national study showed that the impact of the COVID 19 crisis was global on all reimbursed contraceptives, with different levels of impact depending on the type of contraceptive, the age-group and the severity of the restriction. OC dispensing decreased marginally compared with expectations. The decrease in long-acting contraceptives dispensing was more pronounced, especially for the implant. These results call for continued monitoring of contraceptive use over the long term and for prioritizing access to sexual health services during crises, especially among the youngest women who were most affected in this study. The Author(s). Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2023-01-20 /pmc/articles/PMC9851715/ /pubmed/36732137 http://dx.doi.org/10.1016/j.therap.2023.01.002 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Pharmacoepidemiology
Roland, Noémie
Drouin, Jérôme
Desplas, David
Duranteau, Lise
Cuenot, François
Dray-Spira, Rosemary
Weill, Alain
Zureik, Mahmoud
Impact of coronavirus disease 2019 on contraception use in France
title Impact of coronavirus disease 2019 on contraception use in France
title_full Impact of coronavirus disease 2019 on contraception use in France
title_fullStr Impact of coronavirus disease 2019 on contraception use in France
title_full_unstemmed Impact of coronavirus disease 2019 on contraception use in France
title_short Impact of coronavirus disease 2019 on contraception use in France
title_sort impact of coronavirus disease 2019 on contraception use in france
topic Pharmacoepidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851715/
https://www.ncbi.nlm.nih.gov/pubmed/36732137
http://dx.doi.org/10.1016/j.therap.2023.01.002
work_keys_str_mv AT rolandnoemie impactofcoronavirusdisease2019oncontraceptionuseinfrance
AT drouinjerome impactofcoronavirusdisease2019oncontraceptionuseinfrance
AT desplasdavid impactofcoronavirusdisease2019oncontraceptionuseinfrance
AT duranteaulise impactofcoronavirusdisease2019oncontraceptionuseinfrance
AT cuenotfrancois impactofcoronavirusdisease2019oncontraceptionuseinfrance
AT drayspirarosemary impactofcoronavirusdisease2019oncontraceptionuseinfrance
AT weillalain impactofcoronavirusdisease2019oncontraceptionuseinfrance
AT zureikmahmoud impactofcoronavirusdisease2019oncontraceptionuseinfrance